Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Medical Detection Dogs approved for NHS trial
Dog nose
"Our dogs have higher rates of reliability than most of the existing tests. We know their sense of smell is extraordinary" - Dr Claire Guest, Medical Detection Dogs.
Dogs proved 93 per cent effective in detecting prostate tumours

Dogs which have the remarkable ability to sniff-out cancer in humans have been approved for use in an NHS trial.

Medical Detection Dogs gained the approval from Milton Keynes University Hospital following an initial study which revealed that specially trained dogs can detect prostate tumours in urine in 93 per cent of cases.

It is hoped that canine testing will identify inaccuracies in the traditional Prostate-Specific Antigen (PSA) test, which is used to determine if men need a biopsy. The test results are frequently "false positive," meaning that many men are unnecessarily referred for the invasive procedure.

Mr Iqbal Anjum, a consultant urologist at the hospital, said the study was "an extremely exciting prospect".

He added: "Over the years there have been many anecdotal reports suggesting that dogs may be able to detect cancer based on the tumour's odour.

"It is assumed that volatile molecules associated with the tumour would be released into the person's urine, making samples easy to collect and test."

Commenting on the approval,  Dr Clare Guest, co-founder of Medical Detection Dogs, said: "Britain has one of the worst rates of early cancer detection in Europe. The NHS needs to be bolder about introducing new innovative methods to detect cancer in its early stages.

"Our dogs have higher rates of reliability than most of the existing tests. We know their sense of smell is extraordinary. They can detect parts per trillion - that's the equivalent of one drop of blood in two Olympic-sized swimming pools.

"We should not be turning our backs on these highly sensitive bio-detectors just because they have furry coats."

Two charities - the Graham Fulford Charitable Trust and the Prostate Cancer Support Group -  have already expressed their interest in rolling out the diagnostic service once the trial is complete.

Gary Steel, founder of the Prostate Cancer Support Group, said his team were "so impressed" by the initial trials into using dogs to detect cancer, saying the PSA test left "a great deal of room for improvement".

He added: "If they can prove in this study that dogs are reliable at detecting cancer, then we will have the evidence we need to offer sample screening by dogs as an optional test in our cancer clinic.

"We should not miss this opportunity to save thousands of lives."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.